Applied Clinical Trials

Applied Clinical Trials
  • 0.0（0則評分）
  • 生命科學

Go behind the pages of Applied Clinical Trials

  1. 11 小時前

    ACT Brief: Site Relationships and Payment Reliability, AI Adoption Without Governance Risk, and China's Biotech Innovation Rise

    In today's ACT Brief, we examine how unpredictable payments damage site retention, why rapid AI deployment without validation creates regulatory risk, and China's growing dominance in early-stage drug discovery.

    ACT Brief: Site Relationships and Payment Reliability, AI Adoption Without Governance Risk, and China's Biotech Innovation Rise

  2. 1 天前

    ACT Brief: AI in Invoice Processing, Botanical Medicines and FDA Pathways, and Connected Trial Finance Systems

    In today's ACT Brief, we examine where agentic AI delivers immediate wins in site payments, how botanical therapies can earn pharmaceutical credibility, and the connected financial systems reshaping trial operations.

    ACT Brief: AI in Invoice Processing, Botanical Medicines and FDA Pathways, and Connected Trial Finance Systems

  3. 2 天前

    Beyond Compliance: AJNA BioSciences' Joel Stanley on Bringing Botanical Medicine Through the FDA Pathway

    In this episode of Beyond Compliance, Otis Johnson, PhD, MPA, founder and principal consultant at Vantix Operations, speaks with Joel Stanley, CEO of AJNA BioSciences, about why botanical therapies need pharmaceutical-grade standardization and clinical evidence to earn physician trust and insurance coverage.

    Beyond Compliance: AJNA BioSciences' Joel Stanley on Bringing Botanical Medicine Through the FDA Pathway

  4. 2 天前

    ACT Brief: Payment Infrastructure and Site Cash, Inspection Readiness Throughout Execution, and First Hemolytic Anemia Therapy

    In today's ACT Brief, we examine why payment inconsistency persists despite industry awareness, why inspection readiness must be built throughout execution not assembled at submission, and FDA approval of the first disease-specific treatment for a rare blood disorder.

    ACT Brief: Payment Infrastructure and Site Cash, Inspection Readiness Throughout Execution, and First Hemolytic Anemia Therapy

  5. 3 天前

    ACT Brief: Payment Performance as Operational Brand, Speed and Discipline in Biotech Development Strategy, and Non-GLP-1 Obesity Candidate Licensing

    In today's ACT Brief, we examine how payment reliability has become a competitive differentiator at high-performing sites, what a truly strategic lean development model looks like, and a licensing deal for a next-generation obesity therapy combining Phase I data with preclinical validation.

    ACT Brief: Payment Performance as Operational Brand, Speed and Discipline in Biotech Development Strategy, and Non-GLP-1 Obesity Candidate Licensing

  6. 4 天前

    ACT Brief: AI Literacy and Ecosystem Adoption Requirements, CRO Operating Models Under Agentic AI Pressure, and Platform Collaborations in Vaccine and Antibody Discovery

    In today's ACT Brief, we examine the three conditions required for AI-driven trial acceleration to work at scale, why agentic AI will force CRO operating model reckoning, and two major platform collaborations advancing discovery speed.

    ACT Brief: AI Literacy and Ecosystem Adoption Requirements, CRO Operating Models Under Agentic AI Pressure, and Platform Collaborations in Vaccine and Antibody Discovery

  7. 8月21日

    ACT Brief: Trial Failures as Administrative Problems, CRO Consolidation for Global Trial Reach, and FDA Approval of First FOP Treatment

    In today's ACT Brief, we examine where trial failures actually originate and where AI delivers fastest wins, how CRO consolidation creates global operational scale, and the first FDA-approved treatment for a rare progressive bone disorder.

    ACT Brief: Trial Failures as Administrative Problems, CRO Consolidation for Global Trial Reach, and FDA Approval of First FOP Treatment

  8. 8月20日

    ACT Brief: AI Architecture and Model Ownership Due Diligence, FDA Framework for Generative AI Medical Devices, and Heidi Overton Nominated for FDA Commissioner

    In today's ACT Brief, we examine why AI architecture and ownership matter more than model sophistication in clinical development, how the FDA proposes to regulate generative AI-enabled medical devices, and a new leadership appointment at the agency.

    ACT Brief: AI Architecture and Model Ownership Due Diligence, FDA Framework for Generative AI Medical Devices, and Heidi Overton Nominated for FDA Commissioner
顯示全部 (276)

簡介

Go behind the pages of Applied Clinical Trials

資訊

  • 創作者
    Applied Clinical Trials
  • 活躍年代
    2026年
  • 集數
    276
  • 年齡分級
    兒少適宜
  • 節目網站
    Applied Clinical Trials